{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:56:47Z","timestamp":1787504207434,"version":"build-2736575974"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.leukres.2022.106910","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T21:38:58Z","timestamp":1656538738000},"page":"106910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis"],"prefix":"10.1016","volume":"120","author":[{"given":"P.V.","family":"Lipilkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.D.","family":"Kulaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.V.","family":"Mashkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2022.106910_bib1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1080\/16078454.2020.1847801","article-title":"Clinical characteristics and prognostic study of adult acute myeloid leukemia patients with ASXL1 mutations","volume":"25","author":"Lin","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2022.106910_bib2","article-title":"Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases","volume":"5","author":"Gelsi-Boyer","year":"2012","journal-title":"J. Hematol. \\ Oncol."},{"key":"10.1016\/j.leukres.2022.106910_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.12775\/JEHS.2022.12.02.003","article-title":"The current knowledge on ASXL1-mutated acute myeloid leukemia","volume":"12","author":"Andrzejewska","year":"2022","journal-title":"J. Educ. Heal. Sport."},{"key":"10.1016\/j.leukres.2022.106910_bib4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2022.106910_bib5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2022.106910_bib6","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1002\/cam4.2947","article-title":"ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype","volume":"9","author":"Prats-Mart\u00edn","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.leukres.2022.106910_bib7","unstructured":"G.A. Wells, B. Shea, D. O\u2019Connell, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, (n.d.)."},{"key":"10.1016\/j.leukres.2022.106910_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.leukres.2022.106910_bib9","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2010-05-283291","article-title":"Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations","volume":"116","author":"Chou","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106910_bib10","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1182\/blood-2011-08-368225","article-title":"ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category","volume":"118","author":"Metzeler","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106910_bib11","doi-asserted-by":"crossref","first-page":"977","DOI":"10.31557\/APJCP.2022.23.3.977","article-title":"High frequency of ASXL1 and IDH mutations in young acute myeloid leukemia Egyptian patients","volume":"23","author":"El Nahass","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.leukres.2022.106910_bib12","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid\u00a0leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2022.106910_bib13","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2022.106910_bib14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1182\/blood.V118.21.416.416","article-title":"ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an extremely poor outcome","volume":"118","author":"Schnittger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106910_bib15","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2016.65","article-title":"Genetic alterations and their clinical implications in older patients with acute myeloid leukemia","volume":"30","author":"Tsai","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2022.106910_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204218","article-title":"Clinical molecular testing for ASXL1c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era","volume":"13","author":"Montes-Moreno","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2022.106910_bib17","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/leu.2015.198","article-title":"Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing","volume":"30","author":"Cervera","year":"2016","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:33Z","timestamp":1758934953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622001369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":17,"alternative-id":["S0145212622001369"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106910","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106910"}}